ARX-788 is a Monoclonal Antibody Conjugated owned by Ambrx Biopharma, and is involved in 14 clinical trials, of which 13 are ongoing, and 1 is planned.

ARX-788 acts by inhibiting HER-2. It is an antibody drug conjugate (ADC) that functions via the targeted delivery of a cytotoxic payload to the tumor cell or to modulate a specific biological receptor function.

The revenue for ARX-788 is expected to reach a total of $2.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the ARX-788 NPV Report.

ARX-788 is originated and owned by Ambrx Biopharma.

ARX-788 Overview

ARX-788 is under development for the treatment of Her2-positive advanced and HER2 low expressing metastatic breast cancer, gastroesophageal junction adenocarcinoma, esophageal cancer, salivary gland cancer, endometrial cancer, metastatic biliary tract cancer, GE junction carcinoma, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, metastatic pancreatic cancer and gastric cancer. It is administered through intravenous route. The drug candidate is an HER2 specific monoclonal antibody conjugated with Amberstatin 269. The drug candidate is developed based on site-specific conjugation technology.

It was also under development for the treatment of colon cancer, pancreatic cancer, ovarian cancer.

Ambrx Biopharma Overview

Ambrx Biopharma (Ambrx) is a biopharmaceutical company. The company’s pripeline products include anti-HER2 ADC (ARX788), anti-PSMA ADC (ARX517) and anti-CD70 ADC (ARX305). It carries out the research and development of bio-conjugates for animal health, and drugs to treat nonalcoholic steatohepatitis (NASH), heart failure, oncology and immune-oncology diseases. Ambrx creates long acting therapeutic peptides and proteins, modified antibodies and bi-specific fragments through its ReCODE expression system; and larger and complex proteins using its EuCODE expression system. The company works in collaboration with Bristol Myers Squibb, TSRI and Abbvie, Sino Biopharmaceutical, Sino Biopharmaceutical Co Ltd and BeiGene to discover, develop and commercialize antibody-drug conjugates (ADCs). Ambrx is headquartered in La Jolla, California, the US.

The company reported revenues of (US Dollars) US$7.5 million for the fiscal year ended December 2021 (FY2021), a decrease of 45.5% over FY2020. The operating loss of the company was US$64.4 million in FY2021, compared to an operating loss of US$13.1 million in FY2020. The net loss of the company was US$68.1 million in FY2021, compared to a net loss of US$16.5 million in FY2020.

Quick View – ARX-788

Report Segments
  • Innovator
Drug Name
  • ARX-788
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
  • Sponsor Company: Ambrx Biopharma
  • Originator: Ambrx Biopharma
Highest Development Stage
  • Phase III


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.